leflunomide has been researched along with Polyarthritis in 21 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate efficacy and adverse effects of leflunomide for the treatment of naturally occurring immune-mediated polyarthritis (IMPA) in dogs." | 7.76 | Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008). ( Baker, TA; Colopy, SA; Muir, P, 2010) |
| "To examine the effect of leflunomide (LEF) on T cell activation-induced inflammatory cytokine production in human peripheral blood mononuclear cells (PBMC) and rat established adjuvant-induced arthritis (AIA), and compare these effects with methotrexate (MTX) and FK506 (tacrolimus), focusing on improvement of joint function in AIA." | 7.72 | Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. ( Magari, K; Miyata, S; Mutoh, S; Nishigaki, F; Ohkubo, Y, 2004) |
| "The effects of the new immunomodulating isoxazol derivative leflunomide, in comparison with cyclosporin A, on established antigen-induced arthritis in rats as well as serum antibody levels were determined." | 7.69 | Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A. ( Brauer, R; Henzgen, S; Katenkamp, D; Petrow, PK; Thoss, K, 1996) |
| "Combining intra-articular corticosteroid and anti-TNF agent has proved to be safe in our cohort of patients." | 6.75 | Efficacy and safety of combining intra-articular methylprednisolone and anti-TNF agent to achieve prolonged remission in patients with recurrent inflammatory monoarthritis. ( Haroon, M; O'Gradaigh, D, 2010) |
| "Leflunomide is a new immunosuppressive drug recently introduced in the treatment of rheumatoid and psoriatic arthritis." | 5.33 | Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide. ( Lange, U; Müller-Ladner, U; Piegsa, M; Strunk, J, 2006) |
| "In this open study of patients with active AS only those with peripheral arthritis improved significantly with leflunomide treatment." | 5.11 | Six months open label trial of leflunomide in active ankylosing spondylitis. ( Braun, J; Haibel, H; Rudwaleit, M; Sieper, J, 2005) |
| "TTV DNA load was quantified by PCR in a cross-sectional sample of 79 patients with chronic arthritis on biologic therapy (abatacept, infliximab, rituximab or tocilizumab), 31 patients treated with conventional DMARDs (methotrexate and/or leflunomide), and 54 healthy individuals." | 3.96 | Torque teno virus viremia in patients with chronic arthritis: Influence of biologic therapies. ( Aguado, JM; Albert, E; Fernández-Ruiz, M; González-Álvaro, I; Martín-López, M; Navarro, D; Pablos, JL; Rodríguez, E, 2020) |
| "To evaluate efficacy and adverse effects of leflunomide for the treatment of naturally occurring immune-mediated polyarthritis (IMPA) in dogs." | 3.76 | Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008). ( Baker, TA; Colopy, SA; Muir, P, 2010) |
| "To examine the effect of leflunomide (LEF) on T cell activation-induced inflammatory cytokine production in human peripheral blood mononuclear cells (PBMC) and rat established adjuvant-induced arthritis (AIA), and compare these effects with methotrexate (MTX) and FK506 (tacrolimus), focusing on improvement of joint function in AIA." | 3.72 | Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. ( Magari, K; Miyata, S; Mutoh, S; Nishigaki, F; Ohkubo, Y, 2004) |
| "The effects of the new immunomodulating isoxazol derivative leflunomide, in comparison with cyclosporin A, on established antigen-induced arthritis in rats as well as serum antibody levels were determined." | 3.69 | Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A. ( Brauer, R; Henzgen, S; Katenkamp, D; Petrow, PK; Thoss, K, 1996) |
| "Combining intra-articular corticosteroid and anti-TNF agent has proved to be safe in our cohort of patients." | 2.75 | Efficacy and safety of combining intra-articular methylprednisolone and anti-TNF agent to achieve prolonged remission in patients with recurrent inflammatory monoarthritis. ( Haroon, M; O'Gradaigh, D, 2010) |
| "Arthritis in systemic lupus erythematosus (SLE) is episodic and self-limited in most patients." | 2.48 | How to treat refractory arthritis in lupus? ( Artifoni, M; Puéchal, X, 2012) |
| "LEF and/or MTX combined with GPS ameliorated oxidative stress by increasing the mRNA levels of the antioxidant gene Nrf2, GCLC, HO-1, and NQO1, increasing the antioxidant enzymes superoxide dismutase (SOD), glutathione (GSH) and catalase (CAT), reducing the oxidant substance malondialdehyde (MDA), reducing the inflammatory response by decreasing the mRNA levels of NF-κB, tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), and inhibiting the secretion of the pro-inflammatory cytokines TNFα, IL-6, IL-1β and reducing C-reactive protein (CRP), as well as alleviating the external symptoms of arthritis." | 1.62 | Hepatoprotective effect of gentiopicroside in combination with leflunomide and/or methotrexate in arthritic rats. ( Li, H; Li, M; Li, X; Liu, J; Liu, Q; Wan, Z; Wang, R; Wu, X; Zhao, H, 2021) |
| "Episcleritis and scleritis are relatively rare ocular diseases, which are commonly associated with rheumatic diseases including systemic lupus erythematosus (SLE)." | 1.43 | [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus]. ( Jia, Y; Miao, H; Wang, L; Yang, Y; Zhang, XY; Zhou, YS, 2016) |
| "Leflunomide is a new immunosuppressive drug recently introduced in the treatment of rheumatoid and psoriatic arthritis." | 1.33 | Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide. ( Lange, U; Müller-Ladner, U; Piegsa, M; Strunk, J, 2006) |
| " Drug studies were performed, using a 4-day dosing schedule, on optimal DTH elicited on day 10, suboptimal DTH elicited on day 15, and AA (day 16)." | 1.28 | Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. ( Hambleton, P; McMahon, S, 1990) |
| "), dosed for 8 or 16 days beginning with the day of adjuvant administration, significantly reduced edema, fibrinogen levels, and erythrocyte sedimentation rates (ESR) 42 days later." | 1.27 | Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis. ( Buyniski, JP; Gylys, JA; Pasternak, RD; Siminoff, P; Wadopian, NS; Wright, RN, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Wan, Z | 1 |
| Li, H | 1 |
| Wu, X | 1 |
| Zhao, H | 1 |
| Wang, R | 2 |
| Li, M | 1 |
| Liu, J | 1 |
| Liu, Q | 1 |
| Li, X | 1 |
| Martín-López, M | 1 |
| Albert, E | 1 |
| Fernández-Ruiz, M | 1 |
| González-Álvaro, I | 1 |
| Rodríguez, E | 1 |
| Aguado, JM | 1 |
| Navarro, D | 1 |
| Pablos, JL | 1 |
| Cortés-Hernández, J | 1 |
| Egri, N | 1 |
| Vilardell-Tarrés, M | 1 |
| Ordi-Ros, J | 1 |
| Wang, L | 1 |
| Yang, Y | 1 |
| Jia, Y | 1 |
| Miao, H | 1 |
| Zhou, YS | 1 |
| Zhang, XY | 1 |
| Kaul, A | 1 |
| O'Reilly, DT | 1 |
| Slack, RK | 1 |
| Collins, D | 1 |
| Walmsley, J | 1 |
| Duke, O | 1 |
| Kiely, PD | 1 |
| Colopy, SA | 1 |
| Baker, TA | 1 |
| Muir, P | 1 |
| Haroon, M | 1 |
| O'Gradaigh, D | 1 |
| Artifoni, M | 1 |
| Puéchal, X | 1 |
| Bandyopadhyay, D | 1 |
| Magari, K | 1 |
| Miyata, S | 1 |
| Nishigaki, F | 1 |
| Ohkubo, Y | 1 |
| Mutoh, S | 1 |
| Haibel, H | 1 |
| Rudwaleit, M | 1 |
| Braun, J | 1 |
| Sieper, J | 1 |
| Lange, U | 1 |
| Piegsa, M | 1 |
| Müller-Ladner, U | 1 |
| Strunk, J | 1 |
| Sebastiani, M | 1 |
| Giuggioli, D | 1 |
| Vesprini, E | 1 |
| Caruso, A | 1 |
| Ferri, C | 1 |
| Evans, SJ | 1 |
| Webb, D | 1 |
| Lawson, TM | 1 |
| Siebert, S | 1 |
| Li, SG | 1 |
| Kremer, AE | 1 |
| Budenhofer, U | 1 |
| Beuers, U | 1 |
| Rust, C | 1 |
| Thoss, K | 1 |
| Henzgen, S | 1 |
| Petrow, PK | 1 |
| Katenkamp, D | 1 |
| Brauer, R | 1 |
| Hambleton, P | 1 |
| McMahon, S | 1 |
| Hirschelmann, R | 1 |
| Schade, R | 1 |
| Pasternak, RD | 1 |
| Wadopian, NS | 1 |
| Wright, RN | 1 |
| Siminoff, P | 1 |
| Gylys, JA | 1 |
| Buyniski, JP | 1 |
| Bartlett, RR | 1 |
| Schleyerbach, R | 1 |
1 review available for leflunomide and Polyarthritis
| Article | Year |
|---|---|
How to treat refractory arthritis in lupus?
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2012 |
2 trials available for leflunomide and Polyarthritis
| Article | Year |
|---|---|
Efficacy and safety of combining intra-articular methylprednisolone and anti-TNF agent to achieve prolonged remission in patients with recurrent inflammatory monoarthritis.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2010 |
Six months open label trial of leflunomide in active ankylosing spondylitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Ps | 2005 |
18 other studies available for leflunomide and Polyarthritis
| Article | Year |
|---|---|
Hepatoprotective effect of gentiopicroside in combination with leflunomide and/or methotrexate in arthritic rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis; Cytokines; Drug Therapy, Combination; Ir | 2021 |
Torque teno virus viremia in patients with chronic arthritis: Influence of biologic therapies.
Topics: Abatacept; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis; Biologic | 2020 |
Etanercept in refractory lupus arthritis: An observational study.
Topics: Adult; Antirheumatic Agents; Arthritis; Autoantibodies; Cohort Studies; Etanercept; Female; Glucocor | 2015 |
[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinucle | 2016 |
Tolerability of methotrexate and leflunomide combination therapy for inflammatory arthritis in routine clinical practice: results of a four-centre study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis; Drug Therapy, Combination; Female; | 2008 |
Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Autoimmune Diseases; Dog Diseases; Dogs | 2010 |
Exfoliative dermatitis induced by leflunomide therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Dermatitis, Exfoliative; Diagnosis, Differential | 2003 |
Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Bone Marrow Cells; CD28 Antigens; CD3 C | 2004 |
Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide.
Topics: Antibodies, Antinuclear; Arthritis; Autoantibodies; Azathioprine; Drug Therapy, Combination; Female; | 2006 |
Successful treatment with leflunomide of arthritis in systemic sclerosis patients.
Topics: Adult; Antirheumatic Agents; Arthritis; Female; Humans; Isoxazoles; Leflunomide; Middle Aged; Sclero | 2006 |
Renal tubular acidosis associated with leflunomide.
Topics: Acidosis, Renal Tubular; Adult; Antirheumatic Agents; Arthritis; Female; Humans; Isoxazoles; Lefluno | 2007 |
Clinical images: healing of sacroiliitis with leflunomide and sulfasalazine treatment.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Humans; Isoxazoles; Leflunomide; Mal | 2008 |
[A 47-year-old dog breeder with chronic polyarthritis, weight loss and high fever].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2008 |
Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A.
Topics: Animals; Arthritis; Autoantibodies; Cyclosporine; Female; Immunosuppressive Agents; Isoxazoles; Lefl | 1996 |
Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Bacterial; Art | 1990 |
6-Sulfanilamidoindazole arthritis in rats: influence of the new anti-inflammatory agent CGP 28237 and of the immunomodulating compound HWA 486 on degree of arthritis and on acute phase reaction.
Topics: Acute-Phase Reaction; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Experi | 1988 |
Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Experimental; Cyclosporins; | 1987 |
Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat.
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Arthritis, Experimental; Cyclophosphamide; Immunosuppr | 1985 |